1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends

Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market

  • February 2014
  • 52 pages
  • Frost & Sullivan
Report ID: 2013263

Summary

Table of Contents

Rising Incidence of Disease Urges Strong Pipeline Development

Executive Summary

•An aging population contributes to the demand for Parkinson’s disease therapeutics. The available levodopa-based drugs are modestly effective.
•The drugs available or in the pipeline for Parkinson’s are only used to suppress the symptoms as there is still no cure for the disease.
•Genetic targets, namely ’LRRK2’ and ’alpha-synuclein’, offers a promising future cure for the disease.
•Low, unmet therapeutic response to overall Parkinson’s disease therapeutics corresponds to a smaller pipeline investment in comparison to Alzheimer’s disease and other central nervous system (CNS) disorders.
•Market demand for Parkinson’s disease therapeutics is largely generated for the disease modification sector to reduce the onset of symptoms from a disease-eliminating perspective.
•A limited number of available animal models for testing new Parkinson’s disease therapeutics limits the product pipeline for developing disease-eliminating drugs.
•Deep brain stimulation, a surgical procedure, is only conducted on patients suffering from severe Parkinson’s disease and patients with profound medication-induced side effects, such as debilitating dyskinesia.
•Boehringer Ingelheim, GlaxoSmilthKline (GSK), Orion Corporation, Merck & Co, UCB Pharma, and Novartis are some of the key big pharmaceutical competitors in this market.

Methodology and Scope

•This research service focusses on existing therapeutics and the product pipeline for the treatment of Parkinson’s disease using dopamine replacement therapies, dopamine agonists, Monoamine Oxidase (MAO) inhibitors, Catechol O-methyltransferase (COMT) inhibitors and other pharmacological approaches of current global interest. This research service does not cover vaccines.
•A product and pipeline assessment is provided for marketed and investigational products as well as combination regimens for Parkinson’s disease therapeutics. Segmentation by drug class is provided with supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources including the following: disease organisation web sites; public health organisation web sites; company publications, including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

Introduction

Parkinson’s disease is a chronic neurodegenerative disorder with a deceptive onset. The disease is characterised by the gradual loss of motor functions of the body due to the generation of dopamine-producing cells. Postural instability, freezing gait, and difficulty in speech and swallowing are some of the most commonly witnessed symptoms in an individual diagnosed with Parkinson’s disease.
The average incidence rate of the disease is between X and X per X people per year, as per World Health Organisation (WHO) data on Parkinson’s disease. No diagnosis for detecting the onset of the disease has been established yet. Parkinson’s disease commonly occurs to people over the age of X. Differences in the occurrence of the disease are based on environmental risk factors, and the genetic diversity of the global population, which is under the study. Caucasians in North America and Europe report a higher rate of disease prevalence in comparison to Asians in China and Japan. The lowest rate of the disease is recorded among the ethnic groups in Africa.
The disease progresses gradually, with deteriorating motor symptoms giving rise to motor fluctuations and dyskinesia.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Parkinson’s Disease - Market Insights, Epidemiology and Market Forecast – 2025

  • $ 5750
  • Industry report
  • July 2017
  • by Delve Insight

DelveInsight’s “Parkinson’s Disease - Market Insights, Epidemiology and Market Forecast – 2025” Reports provides an overview of the disease and global market size of the Parkinson’s Disease ...

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

  • $ 4950
  • Industry report
  • April 2017
  • by Frost & Sullivan

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases The research service primarily encompasses comprehensive analyses of key emerging therapies ...

Central Nervous System Disorder Drugs Markets in China

  • $ 4000
  • Industry report
  • May 2017
  • by Asia Market Information & Development Company

China’s demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.